Philippe Lehert
Overview
Explore the profile of Philippe Lehert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
2615
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Testelmans D, Lehert P, Asin J, Imschoot J, Causse C, Pepin J
Sleep Med
. 2025 Feb;
129:1-7.
PMID: 39965457
Purpose: Obstructive sleep apnea (OSA) is typically treated with continuous positive airway pressure (CPAP) therapy. Some patients experience residual excessive daytime sleepiness (EDS) under CPAP. Pitolisant demonstrated effectiveness in reducing...
2.
Laperrousaz B, Levast B, Fontaine M, Nancey S, Dechelotte P, Dore J, et al.
BMC Gastroenterol
. 2024 Nov;
24(1):402.
PMID: 39528920
Background: Multiple studies have evaluated fecal microbiota transfer (FMT) in patients with ulcerative colitis (UC) using single-donor (SDN) and multidonor (MDN) products. Systematic review and meta-analysis were performed to compare...
3.
Baud O, Lehert P
Pediatr Res
. 2024 Oct;
PMID: 39448816
Background: Bronchopulmonary dysplasia (BPD) in extremely low gestational age neonates (ELGANs) was associated with neurodevelopmental impairment (NDI). However, the best endpoint of BPD assessment to predict subsequent NDI remains unclear....
4.
Dauvilliers Y, Craig S, Bonsignore M, Barbe F, Verbraecken J, Asin J, et al.
J Sleep Res
. 2024 Oct;
:e14373.
PMID: 39377364
Obstructive sleep apnea (OSA) syndrome commonly leads to excessive daytime sleepiness (EDS). Pitolisant, a selective histamine-3 receptor antagonist, is efficacious at doses up to 20 mg once daily in OSA...
5.
Pepin J, Lehert P, Ben Messaoud R, Joyeux-Faure M, Causse C, Asin J, et al.
EClinicalMedicine
. 2024 Sep;
76:102843.
PMID: 39346006
Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life. Despite first-line treatment with...
6.
Pepin J, Attali V, Causse C, Verbraecken J, Hedner J, Lecomte I, et al.
Chest
. 2023 Nov;
165(3):692-703.
PMID: 37979718
Background: In people with OSA, excessive daytime sleepiness is a prominent symptom and can persist despite adherence to CPAP, the first-line therapy for OSA. Pitolisant was effective in reducing daytime...
7.
Arvis P, Rongieres C, Pirrello O, Lehert P
J Assist Reprod Genet
. 2023 Nov;
41(1):213-222.
PMID: 37921971
Objective: To improve the reliability of prediction models for ovarian response to stimulation in ART. Design: A multicenter retrospective cohort study. Setting: Twelve reproductive centers. Patients: A total of 25,854...
8.
Baud O, Lehert P
Pediatr Res
. 2023 Aug;
95(1):251-256.
PMID: 37653218
Background: Prophylactic low-dose hydrocortisone (HC) was found to improve survival without bronchopulmonary dysplasia (BPD) in extremely preterm infants. However, appropriately adjusting for baseline risks of BPD or death might substantially...
9.
Levast B, Fontaine M, Nancey S, Dechelotte P, Dore J, Lehert P
Clin Transl Gastroenterol
. 2023 May;
14(5):e00568.
PMID: 37232579
Introduction: Patients with ulcerative colitis (UC) have a less diverse microbiome than healthy subjects. Multiple studies have evaluated fecal microbiota transfer (FMT) in these patients using different methods of product...
10.
Dauvilliers Y, Lecendreux M, Lammers G, Franco P, Poluektov M, Causse C, et al.
Lancet Neurol
. 2023 Mar;
22(4):303-311.
PMID: 36931805
Background: Narcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved...